Is there any of that party feeling left?


The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of the pick-up has been so rapid that those who were already positioned in small-cap names started thinking of taking profits, and those who had positioned themselves in big pharma to avoid anticipated market volatility were left second-guessing their defensive strategy. On the one hand, small-cap long-only funds are happy that their thesis seems to be working, and on the other hand long/short hedge funds see the opportunity to short the names which have rallied on newsflow that otherwise would not have impacted share prices. Now, the biggest lingering question is whether the party is over or if there is something left for latecomers.
Despite the general market rally, at Kempen & Co we believe 2012 will be a year for stock picking when it comes to either beating the benchmark or generating an absolute performance in contrast to macro driven 2011 performance. The two major trends in 2012 that will benefit small- and mid-cap names in the Life Sciences sector will be partnering of clinical candidates and cost-cutting/outsourcing. The promise of products with external validation will drive valuations as long as the company has a cash runway of over 12 to 18 months. In partnering scenarios, there will be huge interest for potentially “best-in-class” and “first-in-class” candidates. To illustrate this point, Galapagos has seen its share price double in the last two months on the back of its potentially best-in-class JAK inhibitor. 4SC has seen a recovery in its share price after 2011’s vido­fludimus disappointment in rheumatoid arthritis (RA) as its second drug resminostat reported data showing the potential to treat liver cancer where no other therapy seems to work. It is assumed that the market usually prices-in anticipated partnering deals into a share price after a key positive data point is achieved; however, at Kempen we believe that the companies with best-in-class or first-in-class drugs stand a fair chance of beating those expectations, leading to the share price jumps for which the biotechnology sector is known.
Acquisitions have always taken centre stage in the Life Sciences sector, and we believe 2012 will see Big Pharma cherry-picking in small- and mid-cap space rather than mega-mergers. Antibodies will remain hot, as has already been seen with Amgen’s recent acquisition of Micromet. As far as earnings are concerned, FY11 performed well on a backdrop of positive macro developments, however Q1 guidance has not been as upbeat from corporates as one would expect. A cautious stance from corporates warns of volatility for the coming few months, but Big Pharma’s ever-growing hunger will pave the way for extraordinary returns for small and mid-cap Life Sciences firms.

Tech Review


The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review


Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review


Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review


The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial


Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial


Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Politics / Law


London – The European Medicines Agency (EMA) will publish information about all drugs under review, beginning on March 1. On a monthly basis the company will issue a list disclosing the international non-proprietary name and...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM


Image Gallery

Stock list

All quotes


  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%


  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%


  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%


  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%


  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%


  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week



All Events



BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper